The current contribution of molecular factors to risk estimation in neuroblastoma patients

European Journal of Cancer

Volumn 33, Issue 12, 1997, Pages 2092-2097

  Berthold, F ^a   Sahin K ^a   Hero, B ^a   Christiansen, H ^b   Gehring, M ^b   Harms, D ^b   Horz, S ^a   Lampert, F ^b   Schwab, M ^b   Terpe, J ^b  

^a Ztr fur Kinderonkol und Hamatol   (Germany)

^b NONE

Author keywords

APO 1 (CD95); bcl 2; CD44; DNA ploidy; LOH 1p; MYCN amplification; N ras; Neuroblastoma; NGF R; Risk factors

Indexed keywords

FAS ANTIGEN; HERMES ANTIGEN; NERVE GROWTH FACTOR RECEPTOR; PROTEIN BCL 2;

CANCER GRADING; CHILD; CHILDHOOD CANCER; CONFERENCE PAPER; GENE AMPLIFICATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; ONCOGENE N RAS; PLOIDY; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENES, MYC; HUMANS; INFANT; INFANT, NEWBORN; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031417490     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00237-2     Document Type: Conference Paper

References (27)

1. Christiansen H., Lampert F. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer. 57:1988;121-126.
2. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediat Oncol. 24:1995;215-221.
3. Gehring M., Berthold F., Edler L., Schwab M., Amler L. C. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res. 55:1995;5366-5369.
4. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumour cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group Study J Clin Oncol 1991 9, 581-591.
5. Carlsen N., Ørnvold K., Christensen I. J., Laursen H., Larsen J. K. Prognostic importance of DNA flow cytometrical, histopathological and immunohistochemical parameters in neuroblastomas. Pathol Anat. 420:1992;411-418.
6. Schwab M., Ellison J., Busch M., et al. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci. 81:1984;4940-4944.
7. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313, 1111-1116.
8. Cohn SL, Look AT, Joshi VV, et al. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group Study. Cancer Res 1995, 55, 721-726.
9. Combaret V, Gross N, Lasset C, et al. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 1996, 14, 25-34.
10. Terpe HJ, Christiansen H, Berthold F, et al. Absence of CD44-standard in human neuroblastoma correlates with histological dedifferentiation, N-myc amplification and reduced survival probability. Cell Death Diff 1994, 1, 123-128.
11. Norris MD, Bordow SB, Marshall GM, et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996, 334, 231-238.
12. Kogner P., Barbany G., Dominici C., et al. Co-expression of mRNA for trk proto-oncogene and low affinity nerve growth factor receptor in neuroblastoma with favourable prognosis. Cancer Res. 53:1993;2044-2050.
13. Tanaka T, Hiyama E, Sugimoto T, et al. trk-A gene expression in neuroblastoma. Cancer 1995, 76, 1086-1095.
14. Christiansen N. M., Christiansen H., Berthold F., Lampert F. Transcriptional activity of N-myc and ngf-r in 50 primary human neuroblastomas as predictor for clinical outcome. Int J Oncol. 3:1993;853-857.
15. Tanaka T, Seeger RC, Tanabe M, et al. Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification. Cancer Detect Prev 1994, 18, 283-289.
16. Kusafuka T, Nagahara N, Oue T, et al. Unfavorable DNA ploidy and Ha-ras p21 findings in neuroblastomas detected through mass screening. Cancer 1995, 76, 695-699.
17. Berthold F., Trechow R., Utsch S., Zieschang J. Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. Am J Pediat Hematol/Oncol. 14:1992;207-215.
18. Berthold F., Kassenböhmer R., Zieschang J. Multivariate evaluation of prognostic factors in localized neuroblastoma. Am J Pediat Hematol/Oncol. 16:1994;107-115.
19. Christiansen H., Şahin K., Berthold F., et al. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer. 31:1995;541-544.
20. Cox D. R. Regression models and life tables (with discussion). J R Stat Soc. 34:1972;187-220.
21. Agresti A. Analysis of Ordinal Categorical Data. New York, John Wiley & Sons, Inc., 1984.
22. Christiansen H, Delatte O, Fuchs S, et al. Loss of the putative tumour suppressor-gene locus 1p36 as investigated by a PCR-assay and N-myc amplification in 48 neuroblastomas: results of the German Neuroblastoma Study Group. Prog Clin Biol Res 1994, 385, 19-25.
23. Berthold F., Harms D., Lampert F., Niethammer D., Zieschang J. Risk factors in neuroblastoma of infants. Contrib Oncol. 41:1990;101-117.
24. Sansone R, Strigini P, Badiali M, et al. Age-dependent prognostic significance of N-myc amplification in neuroblastoma. Cancer Genet Cytogenet 1991, 54, 253-257.
25. Hayashi Y., Inaba T., Hanada R., et al. Similar chromosomal patterns and lack of N-myc gene amplification in localized and IV-S stage neuroblastomas in infants. Med Pediatr Oncol. 17:1989;111-115.
26. Nakagawara A., Ikeda K., Higashi K., Sasazuki T. Inverse correlation between N-myc amplification and catecholamine metabolism in children with advanced neuroblastoma. Surgery. 107:1990;43-49.
27. Ambros PF, Ambros IM, Strehl S, et al. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour? Eur J Cancer 1995, 31, 510-515.